

Title of Trial: A phase III, double blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of safinamide (50 to 100 mg/day), as add on therapy, in subjects with idiopathic Parkinson's disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine

Investigational Product: safinamide

Trial No.: 27937

Study Centers: Not available

Trial Initiation Date: 04 May 2009

Trial Completion Date: 04 Jun 2009

Development Phase: Phase 3

Publication (reference): None

Study Objectives: Data not available

Methodology: Data not available

Number of Subjects (Planned and Analyzed): Data not available

Diagnosis and Main Criteria for Inclusion/Exclusion: Data not available

Study Treatment: Data not available

Criteria for Evaluation: Data not available

Statistical Methods: Data not available

Results: Data not available

Conclusions: Data not available

Due diligence was done and all potential information sources have been exhausted. No source documents for this study were identified. Due to non-availability of clinical study reports and synopses, results were not posted in EudraCT database

Merck KGaA

These results are supplied for informational purposes only.